138 related articles for article (PubMed ID: 8067704)
1. Pre- and post- operative adjuvant targeting locoregional chemotherapy combined with locoregional targeting immunostimulation and surgical resection for hepatocellular carcinoma. A new promising alternative.
Lygidakis NJ; Konstantinidou T; Pothoulakis J
Anticancer Res; 1994; 14(3B):1351-5. PubMed ID: 8067704
[TBL] [Abstract][Full Text] [Related]
2. Downstaging Hepatocellular Carcinoma before Transplantation: Role of Immunotherapy Versus Locoregional Approaches.
Lindemann J; Yu J; Doyle MBM
Surg Oncol Clin N Am; 2024 Jan; 33(1):143-158. PubMed ID: 37945140
[TBL] [Abstract][Full Text] [Related]
3. Combination immunotherapy with OK-432, recombinant granulocyte-colony-stimulating factor and recombinant interleukin-2 for human hepatocellular carcinoma.
Himoto T; Watanabe S; Nishioka M; Maeba T; Tanaka S; Saito M
Cancer Immunol Immunother; 1996 Feb; 42(2):127-31. PubMed ID: 8620522
[TBL] [Abstract][Full Text] [Related]
4. Large hepatocellular carcinoma treated with sequential SBRT and immunotherapy with anti-VEGF (Vascular Endothelial Growth Factor) therapy.
Bidarmaghz B; Idrees M; Lee YY; Hodgkinson P
BMJ Case Rep; 2023 Dec; 16(12):. PubMed ID: 38061854
[TBL] [Abstract][Full Text] [Related]
5. Orbital Metastasis as the First Manifestation of Hepatocellular Carcinoma, and Its Effective Treatment with Combined Dual Immunotherapy: A Case Report and Review of the Literature.
Wonglhow J; Dechaphunkul A; Sunpaweravong P; Sathitruangsak C; Pajareeyaphan S; Wetwittayakhlang P
Am J Case Rep; 2024 Jun; 25():e944002. PubMed ID: 38825807
[TBL] [Abstract][Full Text] [Related]
6. [Drug research and development and unmet needs for advanced-stage hepatocellular carcinoma].
Zhou HB; Hu HP
Zhonghua Gan Zang Bing Za Zhi; 2024 Apr; 32(4):306-311. PubMed ID: 38733184
[TBL] [Abstract][Full Text] [Related]
7. Intraarterial combined immunochemotherapy for unresectable hepatocellular carcinoma: preliminary results.
Oka M; Hazama S; Yoshino S; Shimoda K; Suzuki M; Shimizu R; Yano K; Nishida M; Suzuki T
Cancer Immunol Immunother; 1994 Mar; 38(3):194-200. PubMed ID: 8124688
[TBL] [Abstract][Full Text] [Related]
8. A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma.
Faltermeier C; Busuttil RW; Zarrinpar A
Diseases; 2015 Sep; 3(4):221-252. PubMed ID: 28943622
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy as a Complement to Surgical Management of Hepatocellular Carcinoma.
Kim SJ; Cummins KC; Tsung A
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791931
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy Plus Locoregional Therapy Leading to Curative-Intent Hepatectomy in HCC: Proof of Concept Producing Durable Survival Benefits Detectable with Liquid Biopsy.
Raj R; Wehrle CJ; Aykun N; Stitzel H; Ma WW; Krishnamurthi S; Estfan B; Kamath S; Kwon DCH; Aucejo F
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958394
[TBL] [Abstract][Full Text] [Related]
11. Locoregional therapies for hepatocellular carcinoma: The current status and future perspectives.
Chen JJ; Jin ZC; Zhong BY; Fan W; Zhang WH; Luo B; Wang YQ; Teng GJ; Zhu HD
United European Gastroenterol J; 2024 Mar; 12(2):226-239. PubMed ID: 38372444
[TBL] [Abstract][Full Text] [Related]
12. Radionuclide-Labeled Microspheres for Radio-Immunotherapy of Hepatocellular Carcinoma.
Yang S; Mu C; Liu T; Pei P; Shen W; Zhang Y; Wang G; Chen L; Yang K
Adv Healthc Mater; 2023 Oct; 12(26):e2300944. PubMed ID: 37235739
[TBL] [Abstract][Full Text] [Related]
13. Advances in radiotherapy and immunity in hepatocellular carcinoma.
Yang Y; Xiong L; Li M; Jiang P; Wang J; Li C
J Transl Med; 2023 Aug; 21(1):526. PubMed ID: 37542324
[TBL] [Abstract][Full Text] [Related]
14. Imaging for better responses to immunotherapy in hepatocellular carcinoma.
Lindblad KE; Lujambio A
Hepatology; 2023 Jan; 77(1):6-9. PubMed ID: 35727179
[No Abstract] [Full Text] [Related]
15. Annals of Surgical Oncology Practice Guidelines Series: Management of Primary Liver and Biliary Tract Cancers.
Ruff SM; Cloyd JM; Pawlik TM
Ann Surg Oncol; 2023 Dec; 30(13):7935-7949. PubMed ID: 37691030
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant therapy and immunotherapy strategies for hepatocellular carcinoma.
Zhang T; Zhang L; Xu Y; Lu X; Zhao H; Yang H; Sang X
Am J Cancer Res; 2020; 10(6):1658-1667. PubMed ID: 32642282
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy following intrahepatic progression on immunotherapy in advanced hepatocellular carcinoma.
Chan LL; Mok K; Chan SL
J Hepatol; 2024 Jun; 80(6):e282-e283. PubMed ID: 38242325
[No Abstract] [Full Text] [Related]
18. Neoadjuvant targeted immunotherapy followed by surgical resection versus upfront surgery for hepatocellular carcinoma with macrovascular invasion: A multicenter study.
Wu X; Wang Y; Wang S; Chen Y; Han J; Wang C; Zhang M; Hu X; Song B; Wan X; Xu H; Zhao H; Lu X; Mao Y; Sang X; Hong Z; Wei X; Du S
J Cancer; 2024; 15(10):3024-3033. PubMed ID: 38706890
[No Abstract] [Full Text] [Related]
19. Drinking vinegar, a potential adjuvant for immunotherapy of HCC?
Hou J
Hepatology; 2023 Jan; 77(1):3-5. PubMed ID: 35302668
[No Abstract] [Full Text] [Related]
20. Patient-reported symptoms and interest in symptom monitoring in HCC treated with locoregional therapies: A qualitative study.
Moon AM; Cook S; Swier RM; Sanoff HK; Kappelman MD; Wagner LI; Barritt AS; Singal AG; Shah ND; Mauro DM; Yanagihara TK; Gerber DA; Fried MW; Brown C; Waheed M; Teal R; Evon DM
Hepatol Commun; 2023 Nov; 7(11):. PubMed ID: 37930127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
